Table 4.
Changes in metabolic tumor activity for the VOIman during the neoadjuvant treatment between the serial 18F-FDG PET-CT scans
| Parameter | Scan 1 vs. 2 | Scan 2 vs. 3 | Scan 1 vs. 3 | |||
|---|---|---|---|---|---|---|
| Δ | Δ % | Δ | Δ % | Δ | Δ % | |
| SUVmax | − 2.6 (− 6.4 to − 0.5)# | − 37.7 (− 67.7 to − 16.4) | − 0.3 (− 0.5 to − 0.1) | − 13.6 (− 17.5 to − 4.7) | − 3.2 (− 6.7 to − 0.5)# | − 41.6 (− 73.5 to − 27.7) |
| SUVpeak | −2.8 (− 5.6 to − 0.4)# | − 45.8 (− 67.4 to − 17.3) | − 0.2 (− 0.5 to 0.0) | − 9.3 (− 16.8 to 0.4) | − 2.9 (− 5.9 to − 0.3)# | − 45.1 (− 74.4 to − 21.9) |
| SUVmean | − 0.9 (− 1.9 to − 0.1)# | − 39.3 (− 52.0 to − 13.2) | − 0.1 (− 0.2 to 0.0) | − 4.6 (− 17.2 to 2.3) | − 1.0 (− 2.3 to − 0.2)# | − 44.1 (− 57.2 to − 17.0) |
| TLG | − 233.6 (− 637.9 to − 28.0)* | − 52.6 (− 73.6 to − 36.3) | − 18.4 (− 57.0 to − 10.6)# | − 16.3 (− 59.7 to − 5.5) | − 285.0 (− 714.7 to − 34.4)* | − 67.5 (− 82.6 to − 38.2) |
| MATV (ml) | − 22.1 (− 48.2 to 33.5) | − 7.5 (− 44.9 to 23.5) | − 13.2 (− 53.0 to − 5.3)# | − 19.8 (− 49.4 to − 2.7) | − 25.4 (− 70.6 to 27.6) | − 31.2 (− 67.2 to 3.8) |
Data presented as median (IQR)
VOI volume of interest, VOIman manually drawn VOI, 18F-FDG PET-CT fluorine-18-fluorodeoxyglucose positron emission tomography with computed tomography, SUVmax maximum standardized uptake value, SUVpeak peak standardized uptake value, SUVmean mean standardized uptake value, TLG total lesion glycolysis, MATV metabolically active tumor volume, IQR interquartile range. *p < 0.05; #p < 0.01